July 8, 2021, Singapore – Evive Biotech, a global biologics company developing novel biologic therapies, today announces the appointment of Dr. Liping Sun as Senior VP, Global Head of R&D. Dr. Sun brings more than 15 years of experience in drug discovery and development to her role at Evive Biotech, where she will lead the company’s research efforts in early discovery and translational medicine with the goal of enriching the company’s immuno-oncology, inflammatory and metabolic disease pipeline.

Dr. Sun was most recently the Senior Director of Translational Medicine at Harpoon Therapeutics, overseeing IND-enabling studies, translational research, clinical biomarker strategy and operation. She also led cross-functional Product Development Teams to successfully advance TriTAC^® T cell engagers through IND to clinical development. Prior to joining Harpoon, Dr. Sun was at Genentech for over a decade where she led research efforts on multiple T-cell bispecific antibody programs in both hematologic malignancies and solid tumors from concept to development, including Mosunetuzumab that received breakthrough therapy designation in 2020. Dr. Sun received her PhD in Biochemistry from Washington University in St. Louis.

“We are more than delighted to have Dr. Sun join Evive Biotech as the company continues to focus its development efforts on building a global R&D platform,” said Dr. Jubo Liu, CEO of Evive Biotech. “Her extraordinary leadership and extensive experience in the biopharmaceutical industry make her an ideal fit to strengthen Evive’s drug research capability to further our mission to develop revolutionary remedies for patients worldwide. We warmly welcome Dr. Sun to the Evive Biotech family.”

“Evive is a rapidly growing and innovative biopharmaceutical company, and I am very excited to join a passionate and diverse global team,” said Dr. Sun. “I look forward to contributing to our collective efforts in delivering novel therapies with meaningful benefit to patients.” Dr. Sun will be based in the US, while operating from offices in San Francisco, Maryland, and Shanghai. The new office presence in San Francisco will be focused on discovery and early-stage R&D.

About Evive Biotech

Evive Biotech is a global biologics company with Asian roots, developing a portfolio of novel biological therapies for patients worldwide. We leverage our proprietary technology platforms to advance a series of innovative drug candidates for oncology and inflammatory disorders. Founded in 2004, we have over 200 employees today with operations in the US, Singapore and China. We adopt a holistic approach to drug development, combining exceptional research and commercialization capabilities with world class in-house regulatory expertise to bring innovative therapies to market quickly and efficiently. Our state-of-the art in-house cGMP facility allows us to manufacture at commercial scale in accordance with FDA, EMA and NMPA standards and industry best practices. Through partnerships with industry, physicians, and regulatory authorities, we develop revolutionary remedies that we believe will make a real and lasting difference to patients and their families worldwide.

To learn more about Evive Biotech, visit www.evivebiotech.com